Unnecessary Axillary Surgery for Patients With Node-Negative Breast Cancer Undergoing Total Mastectomy | Breast Cancer | JAMA Surgery | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Goyal A, Newcombe RG, Chhabra A, Mansel RE.ALMANAC Trialists Group.  Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer: results of the ALMANAC validation phase.  Breast Cancer Res Treat. 2006;99(2):203-20816541308PubMedGoogle ScholarCrossref
2.
Krag D, Weaver D, Ashikaga T,  et al.  The sentinel node in breast cancer: a multicenter validation study.  N Engl J Med. 1998;339(14):941-9469753708PubMedGoogle ScholarCrossref
3.
Veronesi U, Paganelli G, Viale G,  et al.  A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer.  N Engl J Med. 2003;349(6):546-55312904519PubMedGoogle ScholarCrossref
4.
Gill G.SNAC Trial Group of the Royal Australasian College of Surgeons (RACS) and NHMRC Clinical Trials Centre.  Sentinel-lymph-node–based management or routine axillary clearance? one-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial.  Ann Surg Oncol. 2009;16(2):266-27519050973PubMedGoogle ScholarCrossref
5.
Lyman GH, Giuliano AE, Somerfield MR,  et al; American Society of Clinical Oncology.  American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer.  J Clin Oncol. 2005;23(30):7703-772016157938PubMedGoogle ScholarCrossref
6.
National Comprehensive Cancer Network.  NCCN Clinical Practice Guidelines in Oncology: Breast Cancer: Version 2.2010. Fort Washington, PA: National Comprehensive Cancer Network; 2010
7.
Chen AY, Halpern MT, Schrag NM, Stewart A, Leitch M, Ward E. Disparities and trends in sentinel lymph node biopsy among early-stage breast cancer patients (1998-2005).  J Natl Cancer Inst. 2008;100(7):462-47418364506PubMedGoogle ScholarCrossref
8.
Olaya W, Wong J, Morgan JW,  et al.  Factors associated with variance in compliance with a sentinel lymph node dissection quality measure in early-stage breast cancer.  Ann Surg Oncol. 2010;17:(suppl 3)  297-30220853050PubMedGoogle ScholarCrossref
9.
Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups.  Cancer Causes Control. 2001;12(8):703-71111562110PubMedGoogle ScholarCrossref
10.
Ashikaga T, Krag DN, Land SR,  et al; National Surgical Adjuvant Breast, Bowel Project.  Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection.  J Surg Oncol. 2010;102(2):111-11820648579PubMedGoogle ScholarCrossref
11.
Land SR, Kopec JA, Julian TB,  et al.  Patient-reported outcomes in sentinel node–negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32 [published correction appears in J Clin Oncol. 2010;28(36):5350].  J Clin Oncol. 2010;28(25):3929-393620679600PubMedGoogle ScholarCrossref
12.
Kim HJ, Son BH, Lim WS,  et al.  Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up.  Ann Surg Oncol. 2010;17(8):2126-213120162458PubMedGoogle ScholarCrossref
13.
Krag DN, Anderson SJ, Julian TB,  et al.  Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.  Lancet Oncol. 2010;11(10):927-93320863759PubMedGoogle ScholarCrossref
14.
Olaya W, Wong JH, Morgan JW, Roy-Chowdhury S, Lum SS. Disparities in the surgical management of women with stage I breast cancer.  Am Surg. 2009;75(10):869-87219886124PubMedGoogle Scholar
15.
Edge SB, Niland JC, Bookman MA,  et al.  Emergence of sentinel node biopsy in breast cancer as standard-of-care in academic comprehensive cancer centers.  J Natl Cancer Inst. 2003;95(20):1514-152114559873PubMedGoogle ScholarCrossref
16.
Schonberg MA, Marcantonio ER, Li D, Silliman RA, Ngo L, McCarthy EP. Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival.  J Clin Oncol. 2010;28(12):2038-204520308658PubMedGoogle ScholarCrossref
17.
Kinne DW, Butler JA, Kimmel M, Flehinger BJ, Menendez-Botet C, Schwartz M. Estrogen receptor protein of breast cancer in patients with positive nodes: high recurrence rates in the postmenopausal estrogen receptor–negative group.  Arch Surg. 1987;122(11):1303-13063675194PubMedGoogle ScholarCrossref
18.
Meretoja TJ, Leidenius MH, Heikkilä PS, Joensuu H. Sentinel node biopsy in breast cancer patients with large or multifocal tumors.  Ann Surg Oncol. 2009;16(5):1148-115519242761PubMedGoogle ScholarCrossref
19.
Yi M, Giordano SH, Meric-Bernstam F,  et al.  Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database.  Ann Surg Oncol. 2010;17:(suppl 3)  343-35120853057PubMedGoogle ScholarCrossref
20.
Tan JC, McCready DR, Easson AM, Leong WL. Role of sentinel lymph node biopsy in ductal carcinoma-in-situ treated by mastectomy.  Ann Surg Oncol. 2007;14(2):638-64517103256PubMedGoogle ScholarCrossref
21.
Dominguez FJ, Golshan M, Black DM,  et al.  Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ.  Ann Surg Oncol. 2008;15(1):268-27317891441PubMedGoogle ScholarCrossref
22.
Shapiro-Wright HM, Julian TB. Sentinel lymph node biopsy and management of the axilla in ductal carcinoma in situ.  J Natl Cancer Inst Monogr. 2010;2010(41):145-14920956820PubMedGoogle ScholarCrossref
23.
Halpern MT, Chen AY, Marlow NS, Ward E. Disparities in receipt of lymph node biopsy among early-stage female breast cancer patients.  Ann Surg Oncol. 2009;16(3):562-57018998064PubMedGoogle ScholarCrossref
24.
Naik AM, Joseph K, Harris M, Davis C, Shapiro R, Hiotis KL. Indigent breast cancer patients among all racial and ethnic groups present with more advanced disease compared with nationally reported data.  Am J Surg. 2003;186(4):400-40314553859PubMedGoogle ScholarCrossref
25.
Rescigno J, Zampell JC, Axelrod D. Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy.  Ann Surg Oncol. 2009;16(3):687-69619101768PubMedGoogle ScholarCrossref
26.
Zork NM, Komenaka IK, Pennington RE Jr,  et al.  The effect of dedicated breast surgeons on the short-term outcomes in breast cancer.  Ann Surg. 2008;248(2):280-28518650639PubMedGoogle ScholarCrossref
27.
Specht MC, Fey JV, Borgen PI, Cody HS III. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?  J Am Coll Surg. 2005;200(1):10-1415631914PubMedGoogle ScholarCrossref
28.
Gobbi PG, Broglia C, Carnevale Maffè G, Ruga A, Molinari E, Ascari E. Lymphomatous superficial lymph nodes: limitations of physical examination for accurate staging and response assessment.  Haematologica. 2002;87(11):1151-115612414344PubMedGoogle Scholar
Paper
Sep 2011

Unnecessary Axillary Surgery for Patients With Node-Negative Breast Cancer Undergoing Total Mastectomy

Author Affiliations

Author Affiliations: Division of Surgical Oncology, Department of Surgery, School of Medicine (Drs Olaya and Lum), School of Public Health (Dr Morgan), and California Cancer Registry, Desert Sierra Cancer Surveillance Program, Medical Center (Drs Morgan and Lum), Loma Linda University, Loma Linda, California.

Arch Surg. 2011;146(9):1029-1033. doi:10.1001/archsurg.2011.196
Abstract

Objective To identify factors associated with the use of axillary lymph node dissection (ALND) as the initial axillary staging in node-negative breast cancer patients undergoing total mastectomy.

Design California Cancer Registry study.

Setting Academic research.

Patients Women treated with total mastectomy for Tis, T1, or T2 node-negative breast carcinoma treated between January 1, 2004, and December 31, 2008.

Main Outcome Measures Proportions of patients who underwent ALND without prior sentinel lymph node dissection were compared by demographic characteristics.

Results Of 18 238 women treated with total mastectomy for Tis, T1, or T2 node-negative breast carcinoma, 35.1% underwent initial axillary staging by ALND without prior sentinel lymph node dissection. On multivariable analyses, patients were significantly more likely to undergo ALND if they had T2 disease or were 65 years or older, were hormone receptor negative, of Hispanic or Asian/Pacific Islander race/ethnicity, of lower socioeconomic quintile, operated on during earlier years of the study period, and not treated by a hospital cancer program approved by the American College of Surgeons.

Conclusions More than one-third of patients in California who underwent total mastectomy for treatment of early-stage node-negative breast carcinoma received ALND without prior sentinel lymph node dissection; furthermore, certain subsets of patients have higher odds of undergoing ALND alone. To avoid the unnecessary morbidity of ALND in early-stage breast carcinoma, further research is required to elucidate how tumor, patient, and system factors can be modified to improve delivery of optimal breast cancer care.

×